Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin in Autism Spectrum Disorders
NCT02940574Phase 4Completed
- Sponsor
- KU Leuven
- Start
- Apr 2015
- Primary completion
- Dec 2016
01
Overview
Phase 4, randomised, double-blind trial of oxytocin nasal spray in Autism Spectrum Disorder (ASD), sponsored by KU Leuven. Primary endpoints: Brain Activity During Task at 52 weeks and Brain Connectivity During Rest at 52 weeks. Started Apr 2015; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02940574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02940574.